Key messages
-
Low-dose misoprostol taken orally (by mouth) works similarly to other commonly used methods for starting labour, such as vaginal dinoprostone and oxytocin given into a vein.
-
Compared with misoprostol given vaginally, oral misoprostol may lead to fewer births within 24 hours but may reduce the chance of the uterus contracting too much (hyperstimulation).
-
Oral misoprostol probably leads to fewer caesarean births than balloon or tube devices placed in the cervix, but probably increases the chance of the uterus contracting too much, which can affect the baby.
What is induction of labour?
Inducing labour, or starting labour artificially, is common in pregnancy. It may be recommended to the mother for different reasons, such as if she has high blood pressure or if the pregnancy continues beyond the due date. Labour can be induced using medications or different devices. A good method for starting labour should work well, cause few side effects and have a low chance of ending in a caesarean birth. Some methods do not start labour effectively and lead to more caesarean births, while others cause too many contractions, which can distress the baby.
What is misoprostol?
Misoprostol is a prostaglandin, a hormone-like substance made naturally by the body that helps trigger labour. Misoprostol can be taken in low doses by mouth.
What did we want to find out?
We wanted to find out whether misoprostol taken by mouth is a good way to start labour, compared with other commonly used methods. To do this, we looked at the number of women who had a vaginal birth within 24 hours, the number who needed a caesarean section, and the unwanted event of the number of women who had more than the usual number of contractions that led to changes in the baby's heart rate.
What did we do?
We searched for studies that compared low-dose misoprostol taken by mouth with other methods of starting labour in women in the final three months (third trimester) of pregnancy. We checked all the studies carefully to make sure their data could be trusted. We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as how the studies were designed and their size.
What did we find?
We included 44 studies involving 11,795 women. Most studies took place in hospitals in different healthcare systems, in different countries and compared misoprostol by mouth with no treatment, prostaglandins (either misoprostol or a different one called dinoprostone) given vaginally, oxytocin given into a vein, and balloon or tube devices placed in the cervix.
Compared with no treatment, misoprostol by mouth:
-
probably makes little or no difference to:
-
rates of caesarean birth (3 studies, 294 women); and
-
-
may make little or no difference in:
-
the uterus contracting too much (2 studies, 195 women);
-
-
(none of the studies reported on births within 24 hours).
Compared with the prostaglandin dinoprostone given vaginally, misoprostol by mouth:
-
may result in little or no difference in:
-
births within 24 hours (6 studies, 2492 women);
-
caesarean birth (9 studies, 3185 women); and
-
the uterus contracting too much (7 studies, 2593 women).
-
Compared with misoprostol given vaginally, misoprostol by mouth:
-
may result in reduced:
-
births within 24 hours (11 studies, 2771 women);
-
rates of the uterus contracting too much (16 studies, 3431 women); and
-
-
may result in little or no difference in:
-
caesarean birth (20 studies, 4128 women).
-
Compared with oxytocin given into a vein, misoprostol by mouth:
-
may result in little or no difference in:
-
births within 24 hours (2 studies, 210 women); and
-
caesarean birth (4 studies, 426 women);
-
-
the evidence is very uncertain about the uterus contracting too much (2 studies, 248 women).
Compared with balloon or tube devices placed in the cervix, for misoprostol by mouth:
-
the evidence is very uncertain about births within 24 hours (5 studies, 1273 women);
-
it probably results in fewer:
-
caesarean births (9 studies, 3746 women); and
-
-
it probably increases:
-
the uterus contracting too much (6 studies, 3275 women).
-
When different oral misoprostol regimens are compared:
-
the evidence is very uncertain about birth within 24 hours (1 study, 146 women) and the uterus contracting too much (1 study, 146 women); and
-
giving oral misoprostol with more frequent dosing may result in increased:
-
caesarean births (1 study, 146 women).
-
What are the limitations of the evidence?
Our confidence in these results varies. In some studies, people or staff knew which treatment was being given, which could have affected the results. Some studies did not clearly report how women were assigned to each treatment group. Some comparisons were based on only a small number of studies or events, meaning the true effect could be different from what we found. Sometimes, studies found different results for the same things, which further lowers our confidence.
How up to date is this evidence?
This review updates our previous review from 2021. The evidence is current to April 2025.
Czytaj pełne streszczenie
Wprowadzenie
Misoprostol given orally is a commonly used labour induction method. Our Cochrane Review is restricted to studies with low-dose misoprostol (initially ≤ 50 µg), as higher doses pose unacceptably high risks of uterine hyperstimulation.
Cele
To assess the benefits and harms of low-dose oral misoprostol for labour induction in women with a viable fetus in the third trimester of pregnancy, compared with other methods of labour induction.
Metody wyszukiwania badań
We searched CENTRAL, MEDLINE, Embase, CINAHL, ClinicalTrials.gov and the WHO ICTRP, and checked reference lists of retrieved studies. The search date was April 2025.
Kryteria doboru badań
Randomised trials comparing low-dose oral misoprostol (initial dose ≤ 50 µg) versus placebo, vaginal dinoprostone, vaginal misoprostol, oxytocin, or mechanical methods; or comparing oral misoprostol protocols (one- to two-hourly versus four- to six-hourly; 20 µg to 25 µg versus 50 µg; or 20 µg hourly titrated versus 25 µg two-hourly static).
Zbieranie i analiza danych
Using Covidence, two review authors independently screened reports, extracted trial data, and performed quality assessments. Our primary outcomes were vaginal birth within 24 hours, caesarean section, and hyperstimulation with foetal heart changes.
Główne wyniki
We included 61 trials involving 20,026 women. GRADE assessments ranged from moderate- to very low-certainty evidence, with downgrading decisions based on imprecision, inconsistency, and study limitations.
Oral misoprostol versus placebo/no treatment (four trials; 594 women)
Oral misoprostol may make little to no difference in the rate of caesarean section (risk ratio (RR) 0.81, 95% confidence interval (CI) 0.59 to 1.11; 4 trials; 594 women; moderate-certainty evidence), while its effect on uterine hyperstimulation with foetal heart rate changes is uncertain (RR 5.15, 95% CI 0.25 to 105.31; 3 trials; 495 women; very low-certainty evidence). Vaginal births within 24 hours was not reported. In all trials, oxytocin could be commenced after 12 to 24 hours and all women had pre-labour ruptured membranes.
Oral misoprostol versus vaginal dinoprostone (13 trials; 9676 women)
Oral misoprostol probably results in fewer caesarean sections (RR 0.84, 95% CI 0.78 to 0.90; 13 trials, 9676 women; moderate-certainty evidence). Subgroup analysis indicated that 10 µg to 25 µg (RR 0.80, 95% CI 0.74 to 0.87; 9 trials; 8652 women) may differ from 50 µg (RR 1.10, 95% CI 0.91 to 1.34; 4 trials; 1024 women) for caesarean section. Oral misoprostol may decrease vaginal births within 24 hours (RR 0.93, 95% CI 0.87 to 1.00; 10 trials; 8983 women; low-certainty evidence) and hyperstimulation with foetal heart rate changes (RR 0.49, 95% CI 0.40 to 0.59; 11 trials; 9084 women; low-certainty evidence).
Oral misoprostol versus vaginal misoprostol (33 trials; 6110 women)
Oral use may result in fewer vaginal births within 24 hours (average RR 0.81, 95% CI 0.68 to 0.95; 16 trials, 3451 women; low-certainty evidence), and less hyperstimulation with foetal heart rate changes (RR 0.69, 95% CI 0.53 to 0.92, 25 trials, 4857 women, low-certainty evidence), with subgroup analysis suggesting that 10 µg to 25 µg orally (RR 0.28, 95% CI 0.14 to 0.57; 6 trials, 957 women) may be superior to 50 µg orally (RR 0.82, 95% CI 0.61 to 1.11; 19 trials; 3900 women). Oral misoprostol probably does not increase caesarean sections overall (average RR 1.00, 95% CI 0.86 to 1.16; 32 trials; 5914 women; low-certainty evidence) but likely results in fewer caesareans for foetal distress (RR 0.74, 95% CI 0.55 to 0.99; 24 trials, 4775 women).
Oral misoprostol versus intravenous oxytocin (6 trials; 737 women, 200 with ruptured membranes)
Misoprostol may make little or no difference to vaginal births within 24 hours (RR 1.12, 95% CI 0.95 to 1.33; 3 trials; 466 women; low-certainty evidence), but probably results in fewer caesarean sections (RR 0.67, 95% CI 0.50 to 0.90; 6 trials; 737 women; moderate-certainty evidence). The effect on hyperstimulation with foetal heart rate changes is uncertain (RR 0.66, 95% CI 0.19 to 2.26; 3 trials, 331 women; very low-certainty evidence).
Oral misoprostol versus mechanical methods (6 trials; 2993 women)
Six trials compared oral misoprostol to transcervical Foley catheter. Misoprostol may increase vaginal birth within 24 hours (RR 1.32, 95% CI 0.98 to 1.79; 4 trials; 1044 women; low-certainty evidence), and probably reduces the risk of caesarean section (RR 0.84, 95% CI 0.75 to 0.95; 6 trials; 2993 women; moderate-certainty evidence). There may be little or no difference in hyperstimulation with foetal heart rate changes (RR 1.31, 95% CI 0.78 to 2.21; 4 trials; 2828 women; low-certainty evidence).
Oral misoprostol one- to two-hourly versus four- to six-hourly (1 trial; 64 women)
The evidence on hourly titration was very uncertain due to the low numbers reported.
Oral misoprostol 20 µg hourly titrated versus 25 µg two-hourly static (2 trials; 296 women)
The difference in regimen may have little or no effect on the rate of vaginal births in 24 hours (RR 0.97, 95% CI 0.80 to 1.16; low-certainty evidence). The evidence is of very low certainty for all other reported outcomes.
Wnioski autorów
Low-dose oral misoprostol has similar effects to other commonly used induction methods across most key outcomes. Certainty of the evidence ranged from very low to moderate, mainly due to imprecision and inconsistency. Compared with placebo, vaginal dinoprostone and intravenous oxytocin, oral misoprostol may result in little or no difference in vaginal birth within 24 hours or caesarean section. Compared with vaginal misoprostol, oral misoprostol may reduce uterine hyperstimulation with fetal heart rate changes, but may also reduce vaginal births within 24 hours. Compared with mechanical methods, oral misoprostol probably reduces caesarean section, although it probably increases uterine hyperstimulation with fetal heart rate changes.
Finansowanie
This Cochrane review had no dedicated funding.
Rejestracja
Registration: Protocol PROSPERO (2018) CRD42018092212
Original review (2021) DOI: 10.1002/14651858.CD014484




